Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2019-08-29 Director's Dealing
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Mandatory notification regarding trade of shares
Director's Dealing Classification · 98% confidence The document text explicitly states that a related party (Borkenholm AS, related to board member Hilde Furberg) has bought shares in the company. It details the number of shares (4,000) and the price (NOK 26.90). This transaction involves personal share dealings by an executive/related party and is explicitly stated to be subject to disclosure requirements under securities trading law. This directly matches the definition for Director's Dealing (DIRS). The document length is very short (697 chars), but the content is a direct disclosure of a transaction, not an announcement of a separate report.
2019-08-29 English
PCI Biotech: Mandatory notification regarding trade of shares
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification regarding trade of shares' involving a related party to a board member (Hilde Furberg). This type of filing reports personal share transactions by company directors and executives (insider trades). This directly matches the definition for Director's Dealing (DIRS). The document is short and contains specific transaction details, confirming it is the primary disclosure, not an announcement of a report.
2019-08-29 English
PCI Biotech: Second quarter and first half 2019 results
Report Publication Announcement Classification · 100% confidence The document is an announcement from PCI Biotech regarding their second quarter and first half 2019 results. It provides a summary of operational highlights and clinical study progress, but explicitly states 'Please find enclosed the report and presentation' and includes links to the actual 'PCI Biotech Q2 2019 Interim Report' and 'PCI Biotech Q2 2019 Interim Presentation' as attachments. Following the 'Menu vs Meal' rule, this document is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2019-08-28 English
PCI Biotech: Second quarter and first half 2019 results
Report Publication Announcement Classification · 100% confidence The document is an announcement from PCI Biotech regarding their second quarter and first half 2019 results. It provides a summary of operational highlights and clinical study progress, but explicitly states 'Please find enclosed the report and presentation' and includes links to the actual 'PCI Biotech Q2 2019 Interim Report' and 'PCI Biotech Q2 2019 Interim Presentation' as attachments. Following the 'Menu vs Meal' rule, this document is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2019-08-28 English
PCI Biotech: Second quarter and first half 2019 results
Earnings Release Classification · 99% confidence The document explicitly states: 'PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its second quarter and first half 2019 result. Please find enclosed the report and presentation.' It then lists attachments: 'PCI Biotech Q2 2019 Interim Report' and 'PCI Biotech Q2 2019 Interim Presentation'. The text is an announcement about the release of the Q2/H1 results, not the full report itself. Since it announces the release of a comprehensive report for a period shorter than a year (Q2 and first half 2019), the most appropriate classification is Interim / Quarterly Report (IR). However, the document itself is the announcement *of* the report and presentation, which often falls under Report Publication Announcement (RPA) if the primary purpose is to point to the attached documents. Given the content is substantial (providing key highlights and management commentary) and directly relates to the financial period results, it functions as both an announcement and a summary. Since the definition for IR is 'Comprehensive financial report for a period shorter than a year (e.g., half-year)', and the document announces the *result* and encloses the *report*, classifying it as the result announcement (ER) or the interim report (IR) is plausible. Since it specifically mentions 'second quarter and first half 2019 result' and encloses the 'Interim Report', IR is the best fit for the underlying subject matter, even though it is technically an announcement wrapper. If the document were only the wrapper, RPA would be chosen, but the length and detail suggest it contains the core results summary, aligning it closely with IR. H1 2019
2019-08-28 English
PCI Biotech: Second quarter and first half 2019 results
Investor Presentation Classification · 99% confidence The document is explicitly titled 'Q2 & 1H 2019 PRESENTATION' and contains detailed operational updates for the first half (1H) and second quarter (Q2) of 2019, including clinical trial progress (fimaCHEM, fimaVACC), financial figures comparing Q2 2019/2018 and 1H 2019/2018, and strategic outlook. This structure—a presentation summarizing period performance—is characteristic of an Investor Presentation (IP) or potentially a Management Discussion and Analysis (MDA) if it were a formal regulatory filing. Given the format is a 'PRESENTATION' with slides covering R&D milestones, financial highlights, and technology overview, 'Investor Presentation' (IP) is the most accurate classification. It is not a full Annual Report (10-K) or a standalone Interim Report (IR), but rather the presentation materials used to discuss those results.
2019-08-28 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.